Fungal infections represent an increasing health crisis, especially for immune-deficient patients. American scientists now report in the journal Angewandte Chemie that specific help could be provided by small-molecule immunotherapeutics with novel mechanism of action. They developed small bifunctional molecules that simultaneously bind both chitin, a specific feature of the fungal cell wall and a molecule not found in humans, and naturally occurring human antibodies and redirect the human immune system to eliminate fungal pathogens.
The fungal cell wall is an attractive target for the development of new antifungal drugs because many fungal cell-wall components are not present in humans, enabling exclusive targeting of fungal cells. To obtain the bifunctional molecules called Antibody-Recruiting Molecules targeting Fungi (ARM-F), the Spiegel Research Group at Yale University, USA, modified the key molecule calcofluor-white, a chitin-specific dye used to stain cell walls of fungi, and linked this molecule to a dinitrophenyl (DNP) group. DNP is recognized by human anti-DNP antibodies, which are naturally present in the bloodstream. The resulting chitin, ARM-F, and anti-DNP antibody complex formed is immunogenic and can stimulate effector immune cells, which then mediate the destruction of chitin-expressing fungal cells through phagocytosis.
The team was able to show that ARM-F can bind the model fungal pathogen Candida albicans and recruit anti-DNP antibodies in a dose-dependent manner, without compromising the viability of the cells. They went on to demonstrate that ARM-F has synergistic effects with the antifungal agent caspofungin--a type of echinocandin. Echinocandin-resistant fungi exhibit increased chitin production in the fungal cell wall; thus, the efficacy of ARM-F was even more pronounced when combined with caspofungin. In vitro studies confirmed that phagocytosis of fungal cells by human effector immune cells was increased in the presence of ARM-F.
The specific chitin-targeting mechanism of ARM-F holds promise for fighting echinocandin-resistant fungi, as well as a number of pathogenic fungi. These mechanistically novel small molecules have the potential of serving as an innovative platform for antifungal drug development, both as a single agent or for use in combination with existing antifungal strategies.
###
About the Author
Dr. David A. Spiegel is a Full Professor in the Department of Chemistry at Yale University, New Haven, CT, USA. The Spiegel Research Group focuses on developing synthetic approaches that will help enable our understanding and treatment of human disease.
Journal
Angewandte Chemie International Edition